Department of Nuclear Medicine, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.
Semin Nucl Med. 2010 Mar;40(2):145-52. doi: 10.1053/j.semnuclmed.2009.10.006.
In the past decade, the management of differentiated thyroid carcinoma changed significantly and thus contributed to the improvement of the already favorable prognosis of this malignant disease. Surgical treatment techniques improved and the extent of initial surgery is more individualized. Radioiodine therapy is an essential part of therapeutic regimens in almost all cases, and the use of recombinant human thyroid-stimulating hormone has established for ablation of remnant tissue, treatment of iodine-positive cancer, and sensitive thyroglobulin measurement during follow-up. Risk stratification has become more important to plan treatment and follow-up individually, particularly to evaluate the need for thyroid-stimulating hormone suppression therapy. Especially for inoperable and radioiodine-negative thyroid carcinomas, novel treatment options such as tyrosine kinase inhibitor therapy have emerged. This article deals with the current options of optimal therapy regimens in differentiated thyroid carcinoma.
在过去的十年中，分化型甲状腺癌的治疗发生了显著变化，从而改善了这种恶性疾病已经良好的预后。手术治疗技术得到了改善，初始手术的范围更加个体化。放射性碘治疗几乎是所有病例治疗方案的重要组成部分，而重组人促甲状腺激素的使用已确立用于残余组织消融、碘阳性癌症的治疗以及随访期间敏感的甲状腺球蛋白测量。风险分层对于个体化治疗和随访变得更加重要，特别是评估是否需要促甲状腺激素抑制治疗。对于无法手术和放射性碘阴性的甲状腺癌，新的治疗选择，如酪氨酸激酶抑制剂治疗，已经出现。本文讨论了分化型甲状腺癌的最佳治疗方案的当前选择。
